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Abstract
Purpose Percutaneous vertebroplasty (PV) is a minimally
invasive procedure involving the injection of bone cement
within a collapsed vertebral body. Although this procedure
was demonstrated to be effective in osteoporosis and
metastases, few studies have been reported in cases of
multiple myeloma (MM). We prospectively evaluated the
safety and efficacy of PV in the treatment of vertebral
compression fractures (VCFs) resulting from MM.
Materials and Methods PV was performed in 106 con-
secutive MM patients who had back pain due to VCFs,
the treatment of which had failed conservative therapies.
Follow-up (28.2 ± 12.1 months) was evaluated at 7 and
15 days as well as at 1, 3, 6, 12, 18, and every 6 months
after PV. Visual analog scale (VAS) pain score, opioid use,
external brace support, and Oswestry Disability Index
(ODI) score were recorded.
Results The median pretreatment VAS score of 9 (range
4–10) significantly (P \ 0.001) decreased to 1 (range 0–9)
after PV. Median pre-ODI values of 82% (range 36–89%)
significantly improved to 7% (range 0–82%) (P \ 0.001).
Differences in pretreatment and posttreatment use of
analgesic drug were statistically significant (P \ 0.001).
The majority of patients (70 of 81; 86%) did not use an
external brace after PV (P \ 0.001).
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Conclusion PV is a safe, effective, and long-lasting pro-
cedure for the treatment of vertebral compression pain
resulting from MM.
Keywords Vertebroplasty  Myeloma  Pain treatment 
Interventional radiology  Quality of Life
Introduction
Multiple myeloma (MM) is a blood malignancy caused by
transformation of plasma cells of B-lymphocyte origin that
results in overproduction of monoclonal immunoglobulins.
One of the distinctive features of MM is the production by
malignant plasma cells of several cytokines that directly
activate osteoclasts to remove compact bone, which leads
to osteolytic bone lesions. In fact, bone involvement is
present in 70–100% of patients with MM and is associated
with pain and skeletal-related complications, such as
fractures and hypercalcemia. Despite being an incurable
disease, considerable improvements in the prognosis of
MM have been registered since the introduction of high-
dose chemotherapy with autologous hematopoietic support
[1–4], newer biologically targeted agents, and the use of
zoledronic acid [5]. Despite this recent increase in treat-
ment options, a significant proportion of patients will
eventually develop symptoms of bone progression during
the course of the disease [6]. In fact, overall, bone metas-
tases and their skeletal-related events are not controlled in
approximately 20–40% of cancer patients [7–9], and the
current therapeutic regimens leave B45% of patients with
inadequate or undermanaged pain control [10, 11].
As survival rates in cancer patients improve, painful
vertebral collapse becomes a more pervasive and clinically
significant problem. Vertebral augmentation achieved
through percutaneous vertebroplasty (PV) has become a
mainstay in the treatment armamentarium. PV was first
introduced in 1987 [12] for symptomatic vertebral angioma
and then was used in osteoporotic fracture [13] and
malignancy [14–17]. PV has gained world-wide acceptance
as an effective minimally invasive treatment for back pain
due to vertebral collapse not responding to conservative
treatment. PV involves the injection of radio-opaque bone
cement (polymethylmethacrylate [PMMA]) through a rel-
atively thin needle (13-gauge in this series) within the
collapsed vertebral body under image guidance and
monolateral approach [18]. Kyphoplasty (KP) [19] uses an
inflatable bone tamp generally introduced bilaterally
through a larger cannula before PMMA injection to restore
vertebral height and to decrease PMMA leakage. Pre-
liminary retrospective studies have demonstrated the
effectiveness of PV [16, 20] and KP [21, 22] in controlling
pain and improving the quality of life of patients with
painful MM of the spine. Few studies have prospectively
analyzed the clinical outcomes achieved by PV [23] and
KP [17] in relatively small series of patients. Both proce-
dures are minimally invasive, can be performed with the
patient under local anesthesia, seem to achieve the same
clinical outcome [21] (i.e. pain relief), and have low
complications rates.
Because the majority of MM patients are referred for
vertebral augmentation after other treatments have failed, it
may be necessary to treat patients with poor clinical con-
ditions involving multiple vertebrae. It is the opinion of the
lead author that in such cases, PV, using a thin-needle
unipedicular approach, may be better indicated than KP,
which more typically employs a bipedicular with a larger-
gauge cannula.
PV is currently offered at the lead author’s institution to
patients with MM and symptoms related to spinal bone
involvement that have become refractory to other medical
treatments. The aim of this article is to report the long-term
safety and efficacy of this procedure in a large, prospec-
tively collected series of patients who have C1 painful
vertebral collapse secondary to MM.
Materials and Methods
Study Design and Patient Population
This study was designed as a single cohort using consec-
utive prospectively acquired data examining cement leak-
ages, clinical complications, analgesic drugs requirements,
external brace support, early and long-term pain manage-
ment in patients with MM after PV as a treatment for
osteolytic painful vertebral fractures that were poorly
responsive to conventional therapies.
From 2002 to 2009, 625 consecutive vertebroplasty
procedures were performed in 123 patients (58 women)
with painful vertebral collapse resulting from MM during
145 sessions. 17 patients were lost to follow-up; data were
prospectively collected in 106 patients (50 women) who
underwent 528 consecutive vertebroplasty procedures
during 124 sessions. The mean age was 70.1 years (range,
35–92 years). Indications for PV were painful vertebral
compression fractures (VCFs) in association with myelo-
matous disease not responding to conventional therapies.
Whereas, involvement of the posterior vertebral wall was
not considered as an absolute contraindication; fractures
with retropulsed tumoral tissue or bone fragments causing
symptomatic spinal cord compression were not considered
for PV. The mean duration of symptoms was 11.5 months
(range, 4–23 months). Symptomatic levels were identified
by correlating the clinical interview with magnetic reso-
nance and computed tomography imaging in all patients.
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On average, 4.4 levels were treated per session (range from
1 to 13) from C2 to S1.
Patients were fully informed of potential treatment-related
side complications and provided signed informed consent
before each procedure in accordance with the Declaration of
Helsinki. PV has been offered as a standard palliative treat-
ment at our Institution since 2002. Outcomes data were col-
lected in a prospectively maintained database and this
analysis was approved by the Internal Review Board.
Procedures
PV was performed in most cases (87 of 106 patients; 82%)
using a C-arm angiographic unit (Advantx Tilt-C [GE
Medical Systems, Milwaukee, MN] and Allura X-per CT
[Philips, Best, The Netherlands]) with the patient in the
prone position. Treatment of upper thoracic vertebrae (from
T2 to T4) and the cervical spine was performed under
combined fluoroscopic and computed tomography (CT)
(LightSpeed16; GE Medical Systems) guidance according
to the technique described by Gangi et al. [24]. PV was
performed as previously described in the literature [18].
Bone biopsy, performed coaxially with a thru-cut needle
(Magnum; Bard, New Jersey) before cement injection,
confirmed MM diagnosis in all patients. Only local anes-
thesia was administrated in most cases (104 of 106 patients;
98.1%), whereas general anesthesia (2 of 106 patients;
1.9%) was performed during direct transoral approach
(Fig. 1) to treat the second cervical vertebra. Postprocedural
CT evaluation was performed in all patients to assess ver-
tebral PMMA injection and to evaluate for cement leakage.
An average of 3 ± 1.5 ml PMMA was injected. In
patients with multiple painful vertebral collapses, low-
volume multilevel vertebroplasty, consisting of injecting
\3 ml PMMA (average 1.5 ± 0.5) in each treated verte-
bra, was performed. Our logic was that this would mini-
mize the risk of fat embolism and avoid depression of
hematopoiesis [25, 26].
After the procedure, patients remain at strict bed rest for
2 h and are discharged when they are ready to ambulate,
usually on the same procedural day.
Assessment of Complications and Cement Leakage
Clinical and procedural complications, as well cement
leakages, were recorded prospectively at surgery. Post-
procedural CT scans were performed in all patients to
assess, more precisely than radiographs, local complica-
tions and cement leakages. If a venous cement leakage was
encountered during the procedure, a postoperative CT scan
of the lungs was also acquired to demonstrate pulmonary
vein cement embolism. These data were recorded and
correlated with any clinical symptoms during follow-up.
Follow-Up and Clinical Outcome Evaluation
A dedicated software database was developed to prospec-
tively collect clinical data and technical information on
treated patients. Demographic data, fracture locations, and
treated levels were recorded at each session. Approach,
equipment, cement type, and quantity were detailed for
each treated vertebrae together with any technical or clin-
ical complication.
Follow-up was completed by clinical interview (7 and
15 days after PV) and phone interview (at 1, 3, 6, 12, 18,
and every 6 months). A clinical interview with radiological
imaging was performed if the patients complained of
new-onset back pain.
Fig. 1 Vertebroplasty of C2 with direct transoral approach. CT with
sagittal reconstruction (A) showed the persistence of a painful
osteolytic lesion into the odontoid process of C2 after chemotherapy
and radiotherapy. With a direct transoral approach (B), a 13-gauge
needle is placed within the lesion. Bone consolidation with complete
pain relief and without complication was achieved (C)
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The Oswestry Disability Index (ODI) score, which
represents the level of disability on a scale ranging from 0
(no disability) to 100% (bed bound), was obtained by
means of a self-evaluation questionnaire that was com-
pleted by each patient just before PV (baseline) as well as
at the time of the last interview (end point). Pain was
evaluated with an 11-point pain intensity numerical rating
visual analog scale (VAS) where 0 represents no pain and
10 represents the worst experienced pain. The raw change
in the VAS score was computed by subtracting the baseline
value from the end point for each patient. Farrar et al. [27],
suggested that a decrease of two points in the raw change
scores is clinically relevant. Analgesic drugs prescribed at
baseline and at follow-up interviews were classified as
none, nonsteroidal anti-inflammatory drugs (NSAIDs), oral
narcotics, transdermal, or intravenous (IV) narcotic therapy
with implanted pump.
Statistical Analysis
The outcome of interest was the change, with respect to
pretreatment values, of the following variables at an
average follow-up of 28.2 ± 12.1 months (range 12–72)
after the procedure:
1. The ODI score was studied as a continuous variable
with results rounded to the closest integer [28].
2. The VAS score was studied as both continuous and
categorical ordinal variables.
3. The pattern of analgesic use, which was coded into four
categories: 1 = none, 2 = NSAIDs, 3 = oral opiates,
and 4 = transdermal/IV opiates was studied as both
categorical nominal and categorical ordinal variables.
4. The use of an orthopedic brace was dichotomized into
‘‘yes’’ or ‘‘no.’’
Both the ODI and the VAS values (when treated as a
continuous variable) were not normally distributed, even
after logarithmic transformation. Therefore, for these
variables, medians and ranges were chosen to summarize
the data, and comparisons between pretreatment and
posttreatment values were made by the Wilcoxon test.
Categorical data, either nominal or ordinal, were studied by
contingency tables. Pretreatment and posttreatment values
were compared by the McNemar test (dichotomous vari-
ables), by the marginal homogeneity test (nominal vari-
ables with[2 levels), and by the sign test (ordinal variables
with [2 levels).
The kinetics of pain improvement and the duration of
benefit were studied by drawing Kaplan Meier curves of
time to pain improvement and time to treatment failure.
Time to pain improvement was calculated as the interval
between the procedure and a VAS decrease of C2 points
evaluated at one of the follow-up visits. Time to treatment
failure was calculated as the interval between the procedure
and a VAS increase of C2 points, the onset of new pain, the
need for a new procedure, a serious adverse event requiring
hospitalization, or death in the absence of disease pro-
gression. Significance was set P \ 0.05. Statistical analy-
ses were performed by the SPSS version 17 statistical
package (SPSS, Chicago, IL).
Results
PV was feasible in all 106 patients without any early major
complications, such as death, symptomatic pulmonary
embolism, and spinal or extraspinal tissues injuries.
Two out of 123 patients (1.6%) had a delayed compli-
cation: one patient (excluded from long-term follow-up
study) died from disseminated intravascular coagulopathy
at 10 days after PV, and one patient (included in the study)
developed a bacterial infection (Staphylococcus aureus) of
the treated vertebra 30 days after the PV that required long-
term IV antibiotic chemotherapy.
In five patients (4.7%), a small PMMA embolism to the
lungs was identified on CT scan. All of the cement pul-
monary emboli were asymptomatic at all points, including
immediately after the procedure and during long-term
follow-up; no further treatment was necessary.
Sixteen patients (15%) reported new-onset back pain
during follow-up: X-ray examination and magnetic reso-
nance imaging showed new vertebral collapse associated
with overall disease progression. All new fractures were
successfully treated at a second PV. Amongst the 16
patients, 2 had a further myelomatous vertebral fracture;
thus, they underwent additional PV with apparent success.
Pain and Quality-of-Life Evaluation
Data regarding the variables of interest were available for
the entire data set of 106 patients. The median pretreatment
and posttreatment ODI values were 82% (range 36–89%)
and 7% (0–82%), respectively, and the difference was sta-
tistically significant (P \ 0.001) (Fig. 2). All but 5 patients
achieved an absolute decrease in ODI score, ranging from 7
to 88%, after treatment. 27 patients (26%) achieved an ODI
score of 0% (no disability), and another 64 patients (56%)
achieved an ODI score of\20% (minimal disability).
All of the patients had pretreatment VAS scores C4 or
higher. All but 5 patients achieved a decrease in VAS score
as a result of treatment, with a median decrease of 7 points
(range 0–10). The median pretreatment and posttreatment
VAS values were 9 (range 4–10) and 1 (range 0–9),
respectively, and the difference was statistically significant
by both Wilcoxon test (considering VAS as a continuous
variable [P \ 0.001]) and by signed test (considering VAS
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as a categorical ordinal variable [P \ 0.001]). Notably, 101
patients (95%) achieved a clinically relevant VAS decrease
(C 2); most (95 and 90%) did so within 48 h of the pro-
cedure. 30 patients (28%) achieved resolution of pain
(VAS = 0) (Fig. 3). Figure 4 shows the time to treatment
failure. At 12 months after the procedure, the rate of pain
control was still close to 90%.
Use of Analgesic Drugs
All of the patients were taking analgesic drugs before the
procedure: 59 (56%) of them were on opiates, either oral
(n = 16 [15%]), transdermal (n = 40 [38%]), or IV (n = 3
[3%]). Table 1 lists the type and frequency of analgesic
treatments used before and after treatment. Differences in
pretreatment and posttreatment frequencies in each anal-
gesic drug category were statistically significant by both
marginal homogeneity test (P \ 0.001) and sign test
(P \ 0.001). All but 3 patients achieved a downshift in the
category of analgesic drugs, with 54 patients (51%) not
requiring any analgesic.
External Brace–Support Evaluation
Before treatment, 81 patients wore an orthopedic brace
(76%). As a result of the procedure, 70 of these patients
(86%) no longer use the brace (Table 2, P \ 0.001).
Fig. 2 Boxplots of ODI scores before and after treatment. The
horizontal line in the middle of each box represents the median of the
scores; the length of the box represents the interquartile range; and the
whiskers represent smallest and highest values that are not outliers.
Outliers (values between 1.5 and 3 box lengths) and extreme values
(values that are more than three box lengths away) are indicated by an
open circle and asterisk, respectively. Wilcoxon test P \ 0.001
Fig. 3 Comparison of VAS scores before (dark bars) and after (light
bars) treatment. Wilcoxon test P \ 0.001; signed test P \ 0.001
Fig. 4 Time to treatment failure
Table 1 Analgesic drug use before and after vertebroplasty
Type of analgesic
medication
No. (%)
before PV
No. (%)
after PV
None 0 54 (51)
NSAIDs 47 (44) 46 (43)
Oral opiates 16 (15) 3 (3)
Transdermic/IV opiates 43 (41) 3 (3)
Marginal homogeneity test P \ 0.001; sign test P \ 0.001
Table 2 Joined distribution of brace use before and after
vertebroplasty
Brace after PV
No Yes
Brace before PV No 25 (100) 0 25
Yes 70 (86) 11 (14) 81
95 11 106
Numbers in rows contain represent pretreatment frequencies, and
numbers in columns represent posttreatment frequencies. Numbers in
parentheses represent row percentages. McNemar test P \ 0.001
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Bone Cement Leakage
Postprocedural CT detected a minimal bone cement
extravasation in 121 (22.9%) of the 528 treated vertebrae.
Cross-sectional imaging with CT scans provides the most
complete method of evaluating these leaks. These PMMA
leaks were located in the perivertebral veins (n = 103
[85.1%]), the disc space (n = 7 [5.9%]), and the epidural
vein (n = 11 [9%]). In 5 patients (4.8%) PMMA leaked
through the systemic veins into the lungs. All of these leaks
were asymptomatic during the procedure, at postprocedural
clinical observation, and at final follow-up.
Discussion
In this prospectively acquired database of a series of
patients with MM and uncontrolled symptoms due osteo-
lytic vertebral fractures, the use of PV proved to be safe
and yielded long-lasting clinically meaningful benefits in
the majority of treated patients. Baseline characteristics
portray a group of patients with significant disease-related
disability and pain despite the universal use of analgesic
drugs, mostly consisting of opiates, in more than half of
cases. Significant and durable decreases in disability
scores, pain, and analgesic drug use suggest that PV should
be considered a promising minimally invasive procedure in
this patient setting.
For this analysis we selected patients who had at least
12 months of follow-up after the procedure because our
main aim was to describe whether the benefits related to
PV were durable. This selection did have the effect of
excluding patients with more aggressive or late-stage dis-
ease, with a bias towards better outcomes that must be
taken into consideration in interpreting our findings.
Alternatively, with after-procedural follow-up ranging
from 12 to 72 months (median 28 months), illustrates how
crucial the optimal control of symptoms related to spinal
metastases in patients whose survival can extend from
several months to years after the diagnosis of this
MM-related complication.
VCFs are frequent in MM, and may occur at the onset of
the disease in 34–64% of the patient. Despite antitumor
treatments and the use of bisphosphonates, the median risk
for new fracture may be as high as 14% per year [29].
Severe pain and disability are usually treated with bed rest,
bracing, radiotherapy, and analgesics, with limited benefit
[30]. However, these treatments have been reported to fail
in up to 45% of the cases, leaving patients with insufficient
symptom control and significant disability [10, 11]. Fur-
thermore, radiation therapy may be successful in allowing
bone healing and stabilizing fractured vertebrae, but it
usually takes weeks to months before the spinal column
recovers its weight-bearing capabilities. In patients with
poorly controlled symptoms of vertebral fractures, a
vicious circle can occur where significant disability
decreases compliance to anticancer treatment. In this case
both PV and KP may be an attractive options for pain relief
and faster recovery from fracture-relate disability. No
comparisons are available between these two procedures in
this clinical setting, but, in general, they are considered
equivalent in terms of symptom control [31]. When mul-
tiple procedures are needed in the same patient, due to
frequent presence of multiple collapsed vertebrae, the lead
author believes that PV may be preferred to KP. Compared
with KP, VP is possibly associated with greater incidence
of bone cement leakage. In our series, this event occurred
in approximately 23% of our patients, but it was usually
minimal and with no associated symptoms during after-
procedural follow-up. Obviously, the frequency of bone
cement leakage and of its potential consequences must be
weighed against the overall benefit yielded by PV in this
patient setting.
In conclusion, this study, in line with other reported
retrospective series [16, 20], confirmed that PV is a safe ad
effective treatment for of painful VCFs resulting from the
progression of MM disease. PV produced pain relief and
recovery from moderate to total disability, both of which
were maintained during long-term follow-up. These results,
especially recovery from disability with regain of mobility
and decrease of analgesic drugs use, are likely to translate
into improved patient compliance towards anticancer
treatments.
Although prospective trials are needed to evaluate the
worth of this procedure as an alternative or a complement
to other supportive treatments, the results of our prospec-
tive case series strongly suggest that percutaneous vertebral
augmentation is promising as an elective treatment in MM
patients who suffer from uncontrolled pain and significant
disability due to vertebral fractures.
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